Investigating a new antibiotic for treating respiratory infections
Developing Teixobactin for Respiratory Infections
['FUNDING_R01'] · NOVOBIOTIC PHARMACEUTICALS, LLC · NIH-11035111
This study is looking at a new antibiotic called teixobactin to see how well it can help people with respiratory infections, especially those caused by tough bacteria like MRSA and Streptococcus pneumoniae, particularly in patients with chronic lung issues or those dealing with Covid-19.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NOVOBIOTIC PHARMACEUTICALS, LLC (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11035111 on ClinicalTrials.gov |
What this research studies
This research focuses on teixobactin, a newly discovered antibiotic, to determine its effectiveness in treating respiratory infections, particularly those caused by drug-resistant bacteria like Streptococcus pneumoniae and MRSA. The study aims to explore how teixobactin works against these pathogens, especially in patients with chronic obstructive pulmonary disease and those experiencing co-infections with Covid-19. The research utilizes animal models to predict the appropriate human dosage and assess the antibiotic's efficacy and safety. By targeting specific bacterial components that do not mutate, the research seeks to provide a solution to the growing problem of antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with respiratory infections, particularly those caused by drug-resistant bacteria or co-infections with Covid-19.
Not a fit: Patients with respiratory infections caused by non-bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients suffering from severe respiratory infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in using teixobactin against various bacterial infections, indicating potential for success in treating respiratory infections as well.
Where this research is happening
CAMBRIDGE, UNITED STATES
- NOVOBIOTIC PHARMACEUTICALS, LLC — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUGHES, DALLAS — NOVOBIOTIC PHARMACEUTICALS, LLC
- Study coordinator: HUGHES, DALLAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway infections